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Summary Flavone acetic acid (FAA) showed impressive effects against murine solid tumours but no
activity in clinical studies. The mechanism of action in mice may involve damage to tumour vasculature or
immunomodulation, and these effects may be species-specific. Alternatively, concentrations of FAA achieved
in mouse tumours may be higher than in human tumours. It is important to resolve this issue since it raises
important questions about the relevance of in vitro versus in vivo tumour screens and the development of FAA
analogues. As part of a Cancer Research Campaign Phase II study ofmetastatic melanoma in which 8.4 g m 2
FAA was given as a 6 h infusion, six tumour biopsies were obtained from four patients. FAA tumour
concentrations were determined by HPLC and compared with subcutaneous murine solid tumours within the
same analytical laboratory. Tumour/plasma percentages (range 26-61%; mean ± SD, 43.9 ± 11.4%) were
similar to those in mice, as was the area under the curve (AUC) extrapolated to infinity and the AUC above
the putative activity threshold of 100 jig ml . We conclude that the exposure of drug-refractory human
melanoma tissue to FAA was comparable to that of sensitive mouse tumours. This suggests that reduced
penetration of FAA into human tumours is unlikely to explain the lack of antitumour activity observed in
clinical studies and that differences in mechanism of action are predominant.
Flavone acetic acid (FAA) is a synthetic flavonoid with
impressive activity in preclinical testing against murine
tumours including some quite refractory to conventional
agents (Corbett et al., 1986; Plowman et al., 1986; Bibby et
al., 1988). It attracted substantial interest because of the
likely involvement of a unique mechanism of action (Cumm-
ings & Smyth, 1989; Workman, 1989; Bibby, 1991). The
precise mode of anti-tumour cytotoxicity is uncertain but
may involve indirect effects (Finlay et al., 1988) on tumour
vasculature (Eveloch et al., 1988; Zwi et al., 1989; Bibby et
al., 1989; Murray et al., 1989) or immunological mechanisms
(Wiltrout et al., 1988; Urba et al., 1988; Wiltrout & Hor-
nung, 1988).
Despite encouraging preclinical results, FAA proved com-
pletely ineffective in Phase I and II clinical trials (Kerr et al.,
1987; 1989; Kaye et al., 1990). The reason for this is unclear.
Differences in pharmacokinetics have been observed between
mouse, dog and man (Cummings & Smyth, 1989; Kerr et al.,
1989; Zaharko et al., 1986, Damia et al., 1988; Gouyette et
al., 1988; Chabot et al., 1989). However, plasma concentra-
tions similar to those in mice (>100gLg ml-l) were observed
in human plasma at the doses used in the Phase II studies.
Therefore differences relating to tumour penetration may be
responsible. Alternatively, the vascular or immunomodul-
atory mechanisms may depend on species-specific receptors.
It is important to resolve this issue since it raises questions
about the relevance of in vitro versus in vivo tumour screens
and the development of FAA analogues.
We report the human tumour FAA concentrations
achieved in patients with metastatic melanoma treated in the
Cancer Research Campaign Phase II trial and compare them
with levels observed in mouse tumours in the same analytical
laboratory. Taken together with those of Damia et al. (1990)
the results show that reduced penetration of FAA into
human tumours is unlikely to explain the lack of activity in
clinical studies and that differences in mechanism of action
may predominate.
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Methods
Human studies
Patients Nine patients (six female, three male, age range
28-69 years) were entered into the CRC Phase II study of
FAA in malignant melanoma (Kerr et al., 1989). Metastatic
disease was present in multiple sites including skin (seven soft
tissues, four lymph nodes, three lung, two liver, peritoneum,
brain, bone and a local recurrence. Liver and renal function
were within normal limits. Patients received 8.6 gm-2 FAA
in a 6 h infusion with urine alkalinisation (sodium bicar-
bonate; 500 ml, 1.26%; 1 h before and after infusion of
FAA). Dose reduction to 6.4 g m-2 was applied in two
patients following drug-induced hypotension during the first
infusion of FAA. Treatment was repeated weekly to a max-
imum of six infusions. No evidence of tumour response was
observed in any patient.
Plasma concentrations Full pharmacokinetic profiles were
obtained on 8/9 patients and a partial time course in the
ninth.
Five ml of heparinised blood was collected at the start, the
mid point and the end of the infusion (EOI) of FAA.
Thereafter further samples were collected at 5, 15, 30, 60,
90 min, 2, 3, 4, 6, 14 and 24 h after EOI. Plasma was stored
at -20°C until analysis.
Tumour concentrations With patient's informed consent, six
tumour samples were obtained from 4/9 patients to deter-
mine FAA concentration. Excision of cutaneous or sub-
cutaneous metastases was performed under local anaesthetic.
Sampling times were at EOI in two cases, and at 10, 22 and
65 min and 12 h after EOI. The samples were subdivided and
frozen at - 70°C until analysis.
Mouse studies
Plasma and tumour concentrations C3H/He mice bearing
subcutaneously transplanted KHT sarcomas (range
300-400 mm3) were treated with 200 mgkg-' (600 mg m-2)
FAA by intraperitoneal (ip) injection 10-12 days after sub-
cutaneous innoculation. Groups of three mice were then
sacrificed at 5, 15, 30min, 1, 2, 4, 6, 8, 12 and 24h after
injection. C3H/He mice bearing transplanted RIF-1 and 16C
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tumours and BALB/c mice bearing EMT6 mammary
tumours were treated with 250 mg kg-' (750 mg m-2) FAA
and sacrificed at 30 min for tumour and plasma FAA
concentrations. These doses represent the highest therapeutic
doses normally used in tumour bearing mice. Mice were
exsanguinated under terminal diethyl ether anaesthesia and
tumours were removed immediately after. Samples were
stored as described above for human tissue. Experiments
were independently replicated.
FAA analysis FAA concentrations were determined by a
modification of the high performance liquid chromatography
method of Cummings et al. (1988). Tumours were thawed,
finely chopped and then homogenised rapidly on ice with
3-6 vol 10mM ammonium acetate buffer, pH 5.3, using an
all-glass homogeniser. After this the homogenate was treated
as for plasma. Samples (100gl) were mixed with the above
buffer (200 il) containing 4-(dimethylamino) benzaldehyde
(300 gg ml-') as internal standard. Aliquots (1001il) were
loaded onto C18 cartridge columns (Sep-Pak, Waters Assoc.,
Milford, MA) previously washed with methanol (5 ml) and
ammonium acetate buffer (2 ml). After washing with buffer
(1 ml) the analytes were eluted with methanol (1 ml).
Chromatography was carried out using modular equipment
from Waters Assoc. Separation was achieved with a
Novapak C,8 cartridge column (10 cm long; 8 mm i.d.; 4 mm
bead size) and a mobile phase of 23% propanol in 10 mM
ammonium acetate buffer, pH 5.3. Peak assignments were
made on the basis of retention time and spectral properties
and no interfering peaks were seen. Extraction efficiences
were 83% for spiked tumour homogenate, sensitivity was
3 gig ml-' and calibration curves were linear over the
required range.
concentrations at the end ofinfusion and after 30 m were 378
and 306 gig ml-. The average elimination half life (tp) was
5.4 h and the AUCO. was 3612 gigml-' h. Pharmacokinetics
were closely comparable to those reported in the Phase I
studies (Kerr et al., 1987). The mean AUC above the postu-
lated activity threshold (Zaharko et al., 1986) of 100 gg ml-'
was 1865 gig ml-' h. A typical time course is illustrated in
Figure 1.
FAA concentrations from the six melanoma tumour sam-
ples are shown in Table II. Analysis of divided tumours
demonstrated excellent reproducibility. Average tumour con-
centrations achieved between the EOI and 65 min thereafter
ranged between 122 and 183 gig FAA per gram. The sample
taken 12 h after the EOI showed a mean tumour concentra-
tion of 20.1 gig g-'. The tumour to plasma percentages for
the samples from EOI to 65 min were closely grouped with a
mean of 47.5 (± 7.9, SD)%. The value at 12 h was 25.7% in
the single specimen analysed. The overall tumour to plasma
percentage including the 12 h point was 43.9 (± 11.4,
SD)%.
Concentrations were determined in plasma and tumour in
mice bearing four different subcutaneous transplanted mouse
tumours 30 m after 250 mgkg-' (750 mg mi-2) ip. Mean
tumour levels ranged from 276-332 gg-' and the tumour/
plasma percentages were 48.6 ± 12.6 for EMT6, 62.7 ± 11.4
for RIF-1, 56.7 ± 5.9 for 16C and 58.5 ± 30.3 for KHT
(± SD, n = 5-8). Detailed pharmacokinetic parameters were
determined (Figure 2a and Table III). Maximal tumour con-
centrations were achieved at 1 h (424.3 gg g-') with an
1000.
Pharmacokinetic analysis Pharmacokinetic parameters were
calculated by nonlinear regression analysis using Subroutine
VCO5AD of the Harwell Subroutine Library. Parameters
were derived from standard equations (Wagner, 1975). Area
under the curve (AUC) above 100 gig ml-' was calculated
using the trapezoidal method.
Tumour blood flow assessment Relative tumour perfusion
was assayed in mice bearing KHT sarcomas after ip injection
of 200 mg kg-' (600 mgM-2) FAA, by 86rubidium (Sapirs-
tein, 1958). Briefly, approximately 8 iLCi 86RbCl were injected
i.v. and the mouse was killed 60 sec later. Tumours were
excised, weighed and counted in a Wallace 1282 Compu-
gamma counter. Groups of 12-16 mice were used for each
time point. The percentage of injected counts per gram of
tumour was calculated, and means and standard errors were
calculated for each group and subsequently expressed as a
percentage of the mean of the control group.
Results
Plasma pharmacokinetic parameters in the eight patients with
full time courses are shown in Table I. Mean plasma FAA
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Figure 1 A typical time course of plasma FAA concentration
versus time following a 6h infusion of 8.4 mg m2 in a patient
with malignant melanoma.
Table I Plasma pharmacokinetic parameters in eight patientsa receiving 8.6gm-2 FAA
Patient Peak 30 min t1e tip AUC0 , AUC> Zoo Cl Vda,ea
no. g ml- gig ml-' min h igml-'h iLgml-'h h-' I
1 358.9 285.1 57.4 5.19 3005 1563 4.49 33.6
2 439.4 338.6 22.9 6.59 4992 2157 2.80 26.7
3 460.8 415.5 41.6 4.04 3976 2462 3.27 19.1
4 409.2 393.6 7.20 4.76 4476 2226 3.93 27.0
5 233.6 173.2 63.7 8.02 1998 5925 7.06 81.0
6 340.5 291.3 44.3 2.55 2795 1687 4.5 16.6
7 283.4 247.0 96.7 7.25 2383 1148 5.75 60.2
8 500.0 456.5 31.7 4.67 5268 3082 2.52 17.0
Mean 378.2 306.3 45.7 5.38 3612 1865 4.29 35.2
SD 91.07 84.16 27.5 1.80 1235 785 1.53 23.3
aOnly two time points were available from patient 9.
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Table II Tumour and plasma concentrations of FAA in human melanoma
Pt Time after Tumour plasma Tumour/plasma
no. EOI (Ltg-') (mean) (ILgml-,) (%) (mean)
8a 0 196.8 183.4 390 50.5 47.1
157.3 40.4
196.6 50.3
7 0 114.1 131.8 283 40.2 46.6
123.0 43.4
122.3 43.1
165.4 58.4
134.3 47.4
9 10 min 183.3 178.7 429 42.7 41.6
174.1 40.6
6 22 min 125.1 120.5 290 43.1 41.5
116.5 40.1
119.9 41.3
8a 65 min 169.0 176.3 290 58.3 60.8
183.6 63.4
8a 12 h 14.5 20.1 78 18.5 25.7
20.1 25.7
23.6 30.1
22.4 28.7
aThree samples taken from one patient after three different infusions.
elimination ti of 5.8 h. At 1-6 h the tumour/plasma % was
constant with a mean of 73%. Thereafter, the tumour con-
centration fell more slowly than the plasma concentration,
such that tumour exceeded plasma at these late times.
Tumour/plasma percentages at 12 and 24h after injection
were 452% and 852% respectively. Similar results were
obtained in a repeat experiment using 200 mg kg-'
(600mgm2) FAA (data not shown).
Parallel studies of KHT tumours after 200 mg kg-'
(600 mg m 2) ip FAA showed a rapid decline in the relative
tumour blood flow. A nadir of 5% of control was observed
at 6 h, followed by a slow recovery to 20% at 24 h (Figure
2B). No significant alteration occurred in a range of normal
tissues (data not shown). Doses of 200 and 250 mg kg-'
(600-750mgM-2) FAA ip resulted in regrowth delays of
around 3-5 days in KHT sarcomas, compatible with the
previously reported efficacy of FAA in murine tumours (Cor-
bett et al., 1986; Plowman et al., 1986; Bibby et al.,
1988).
In contrast to plasma (Cummings et al., 1988; Cummings
& Smyth, 1989), no metabolites of FAA were detected in
either human or mouse tumours.
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Table III Pharmacokinetic parameters in mice with KHT tumours
receiving 200mg kg-' (600mgmi-2) ip FAA
Peak
sgmlt'
Plasma 965.3
Tumour 431.0
Co
jgmltI
734.6
348.3
ti
h
2.8
5.8
AUCo0
tgml-
I h
or igg-'h
2985
2790
AUC> lo
pgml-' h
or Lgg-'h
1816
9834
Discussion
One possible explanation for the marked discrepancy
between the impressive effects of FAA against transplanted
murine solid tumours (Corbett et al., 1986; Plowman et al.,
1986; Bibby et al., 1988) and the absence of activity in
human studies (Kerr et al., 1987; 1989; Kaye et al., 1990) is a
difference in tumour drug exposure between mice and
humans. This study has shown a close parallel between the
plasma exposures in the two species. Mean AUCO-,, was
3612,.g ml' h in the patients and 2985 yg ml-' h mice.
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Figure 2 FAA concentration versus time following ip injection of 250 mg kg-' (750 mgm-2) in mice bearing KHT sarcomas.
Open circles: plasma concentration (± lSD) lagml-'; triangles: tumour concentrations (± ISD) Lgg-'. A parallel experiment to
show effects on tumour blood flow by rubidium extraction after ip injection of 200 mg kg-' (600 mgm-') FAA.582 T.S. MAUGHAN et al.
Similarly, above the postulated threshold of 100ILgml-l
(Zaharko et al., 1986) the plasma drug exposures were highly
comparable, being 1865 and 1816fg ml-' h in humans and
mice respectively. Tumour/plasma percentages were found to
be marginally higher in the case ofmouse tumours (48-63%)
but of similar magnitude to that observed in humans (mean
47.5%) at early time points. The peak (30 min) tumour con-
centrations in murine tumours (300lg g-1) were higher by a
factor of 2 compared with the melanoma deposits over the
first hour after EOI (150fig g-1). After 6 h, there was a
reproducible and marked elevation in the tumour/plasma
percentages for the KHT tumour. This was not seen in the
single melanoma biopsy obtained at 12 h, where the value
was 25%. The elevation in the tumour/plasma percentages
for the KHT tumour coincided with the abrupt fall in
tumour blood flow, as noted previously in sensitive mouse
solid tumours (Corbett et al., 1986; Plowman et al., 1986;
Bibby et al., 1988). Thus, it seems possible that the rise in
tumour/plasma percentages was due to the trapping of FAA
in KHT tumours as a result of the reduction of blood flow.
Although it was only possible to obtain a single late time
point in the human tumour study, the relatively low value
there suggested that this trapping effect may not be seen in
man.
It is particularly interesting to compare the exposures to
FAA in the mouse and human tumours. The AUCO, for
the murine KHT tumour was 2790ltg g-' h. This is similar
to that of 1733jig g-' h for the human melanomas estimated
as the product of the average plasma AUCO-,0, and the mean
tumour/plasma ratio of 0.48. The corresponding values
above the putative activity threshold showed even closer
agreement at 983fig g-' h for the mouse KHT tumour and
895 ± 377(SD) ttg g- I h for human melanomas. Thus the
mouse and the predicted human FAA exposures are very
similar. We have to emphasise however that we have only a
single human melanoma value for time points beyond 1 h
and further data for later times would be useful to confirm
our prediction.
The mouse plasma and tumour exposures obtained in the
present study are similar to those reported previously (Damia
et al., 1988; Chabot et al., 1989). For example, Damia et al.
(1988) observed a plasma AUCo_0 (± SE) of
2021 ± 166 tgml-' h and a tissue/plasma % for the mouse
PAN/03 tumour of 57% after 200 mg kg-' (600 mg m-2)
FAA. The Mario Negri group also reported the only other
published data for human tumour FAA levels (Damia et al.,
1990). They obtained biopsies of primary or metastatic
tumour for six patients, in all cases 2 h after a 1 h infusion of
4.8 g m-2 FAA in an EORTC ECTG study. Tumour/plasma
percentages ranged from 25-80% and the mean of 45.8
(± 24.5 SD)% was almost identical to the present study.
Taken together with previous experience, our studies
appear to rule out inadequate tissue exposure as a cause of
the lack of activity of FAA in human compared to mouse
tumours. A species-specific mechanism, presumably involving
the tumour vasculature or the immune system, may be re-
sponsible. Alternatively, the various effects of FAA seen in
rodents may be a feature of transplantable tumours, rather
than a species difference per se.
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